[Asia Economy Reporter Lee Jung-yoon] Access Bio announced on the 23rd that it has signed a supply contract worth KRW 55,637,920,000 for COVID-19 antigen self-test kits with the Defense Logistics Agency Troop Support Medical, a procurement agency under the U.S. Department of Defense that supports the supply of medical supplies to the U.S. military.
This amount corresponds to 11.01% of the consolidated sales as of the end of last year, and the contract period is until November 22, 2023.
▲ Ildong Pharmaceutical = Emergency use approval by Japan's Ministry of Health, Labour and Welfare for Shionogi Pharmaceutical's oral COVID-19 treatment drug Zokova (S-217622)
▲ SK Bioscience = Regarding reports on the suspension of production of Korea's first COVID-19 vaccine, the company explained that vaccines are produced separately as bulk and finished products, and after bulk production, finished products are produced and supplied according to market demand. Skycovione, which has obtained domestic product approval, has not produced additional finished products after the initial batch due to low vaccination rates, but plans to resume production and supply upon government request. The company also stated that it is proceeding with global approval procedures for overseas sales.
▲ Hanshin Engineering & Construction = Won a contract worth KRW 67,760,000,000 for the Daeyeon Station Street Housing Redevelopment Project from the Daeyeon Station Street Housing Redevelopment Project Association
▲ DNT = Signed a supply contract worth KRW 29,900,000,000 for secondary battery manufacturing equipment with Ultium Cells LLC
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
